Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.

abstract：:Several tyrosine kinases such as Jak1, Jak3, Lck and Syk are known to participate in IL-2-mediated intracellular signal transduction. Jak1, Lck and Syk are associated with the cytoplasmic domain of the beta chain, whereas Jak3 is associated with the cytoplasmic domain of the gamma chain, which is shared among receptor...

journal_title：Leukemia

authors： Higuchi M,Asao H,Tanaka N,Oda K,Takeshita T,Sugamura K

更新日期：1997-04-01 00:00:00

abstract：:Activating mutations in NOTCH1 are found in over 50% of human T-cell lymphoblastic leukemias (T-ALLs). Here, we report the analysis for activating NOTCH1 mutations in a large number of acute myeloid leukemia (AML) primary samples and cell lines. We found activating mutations in NOTCH1 in a single M0 primary AML sample...

journal_title：Leukemia

authors： Palomero T,McKenna K,O-Neil J,Galinsky I,Stone R,Suzukawa K,Stiakaki E,Kalmanti M,Fox EA,Caligiuri MA,Aster JC,Look AT,Ferrando AA

更新日期：2006-11-01 00:00:00

abstract：:Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate ant...

journal_title：Leukemia

authors： Wild J,Schmiedel BJ,Maurer A,Raab S,Prokop L,Stevanović S,Dörfel D,Schneider P,Salih HR

更新日期：2015-08-01 00:00:00

abstract：:CD13/aminopeptidase N (APN) is a cell surface metallopeptidase expressed by normal and leukemic myeloid cells, and by lymphoblasts in 5-10% of acute lymphoid leukemia (ALL) cases, previously classified as 'biphenotypic' or 'mixed-lineage' leukemias. In fresh cells from two early B-lineage, t(9;22)-positive, ALL cases ...

journal_title：Leukemia

authors： Saito M,Kumagai M,Okazaki T,Nakazawa S,Shapiro LH,Look AT,Campana D

更新日期：1995-09-01 00:00:00

abstract：:The activation of natural killer (NK) cells leads to degranulation and secretion of cytotoxic granula. During this process, the lytic granule membrane protein CD107a becomes detectable at the cell surface. Based on this phenomenon, we have analyzed by a novel flow cytometry-based assay, the number and phenotype of NK ...

journal_title：Leukemia

authors： Penack O,Gentilini C,Fischer L,Asemissen AM,Scheibenbogen C,Thiel E,Uharek L

更新日期：2005-05-01 00:00:00

abstract：:Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis to determine predictive factors for TLS. In 116 patients, the incidence of TLS was 46% (95% CI: 36-55%). In uni...

journal_title：Leukemia

authors： Blum KA,Ruppert AS,Woyach JA,Jones JA,Andritsos L,Flynn JM,Rovin B,Villalona-Calero M,Ji J,Phelps M,Johnson AJ,Grever MR,Byrd JC

更新日期：2011-09-01 00:00:00

abstract：:The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

journal_title：Leukemia

authors： Zhan H,Ma Y,Lin CH,Kaushansky K

更新日期：2016-12-01 00:00:00

abstract：:Chronic myeloid leukemia (CML) relapse after allogeneic stem cell transplantation (SCT) is a relatively frequent situation, which is correlated to disease status, time from diagnosis to transplant and T-cell depletion. We evaluated the potential for early minimal residual disease (MRD) BCR-ABL quantification to predic...

journal_title：Leukemia

authors： Asnafi V,Rubio MT,Delabesse E,Villar E,Davi F,Damaj G,Hirsch I,Dhédin N,Vernant JP,Varet B,Buzyn A,Macintyre E

更新日期：2006-05-01 00:00:00

abstract：:Remarkable progress has been achieved in the characterization and isolation of primitive hematopoietic stem cells (HSC). HSC represent a very small subset of hematopoietic cells and provide self-renewal, possess differentiation capacity and allow a constant supply of the entire hematopoietic cell spectrum. Until recen...

journal_title：Leukemia

authors： Engelhardt M,Lübbert M,Guo Y

更新日期：2002-09-01 00:00:00

abstract：:Arsenic trioxide (ATO) induces disease remission in acute promyelocytic leukemia (APL) patients, but not in non-APL acute myeloid leukemia (AML) patients. ATO at therapeutic concentrations (1-2 μM) induces APL NB4, but not non-APL HL-60, cells to undergo apoptosis through the mitochondrial pathway. The role of antiapo...

journal_title：Leukemia

authors： Wang R,Xia L,Gabrilove J,Waxman S,Jing Y

更新日期：2013-02-01 00:00:00

abstract：:The Wilms' tumor gene, WT1, is a tumor marker for leukemic blast cells. The WT1 expression levels were examined for 57 patients with myelodysplastic syndromes (MDS) (refractory anemia (RA), 35; RA with excess of blasts (RAEB) 14; RAEB in transformation (RAEB-t), six; and MDS with fibrosis, two) and 12 patients with ac...

journal_title：Leukemia

authors： Tamaki H,Ogawa H,Ohyashiki K,Ohyashiki JH,Iwama H,Inoue K,Soma T,Oka Y,Tatekawa T,Oji Y,Tsuboi A,Kim EH,Kawakami M,Fuchigami K,Tomonaga M,Toyama K,Aozasa K,Kishimoto T,Sugiyama H

更新日期：1999-03-01 00:00:00

abstract：:Infants <1 year of age have a high prevalence of prognostically unfavorable leukemias and a presumed susceptibility to treatment-related toxicities. A total of 125 infants with acute myeloid leukemia (AML) were treated in studies AML-BFM-98 (n = 59) and -2004 (n = 66). Treatment regimens of both studies were comparabl...

journal_title：Leukemia

authors： Creutzig U,Zimmermann M,Bourquin JP,Dworzak MN,Kremens B,Lehrnbecher T,von Neuhoff C,Sander A,von Stackelberg A,Schmid I,Starý J,Steinbach D,Vormoor J,Reinhardt D

更新日期：2012-04-01 00:00:00

abstract：:Previous studies demonstrated that triazene compounds (TZC) possess antitumor, antimetastatic and immunosuppressive activity, and induce novel antigenic properties in neoplastic cells. Moreover, TZC showed marked antitumor activity in patients with acute myelogenous leukemias (AML). In most cases leukemic blasts with ...

journal_title：Leukemia

authors： Tentori L,Graziani G,Gilberti S,Lacal PM,Bonmassar E,D'Atri S

更新日期：1995-11-01 00:00:00

abstract：:In this open-label randomized clinical trial, HLA-identical sibling-matched hematopoietic stem cells (HSC) were transplanted (non-MSCs group, n=15) or cotransplanted with mesenchymal stem cells (MSCs) (MSCs group, n=10) in hematologic malignancy patients. The median number of MSCs infused was 3.4 x 10(5) kg(-1) (range...

journal_title：Leukemia

authors： Ning H,Yang F,Jiang M,Hu L,Feng K,Zhang J,Yu Z,Li B,Xu C,Li Y,Wang J,Hu J,Lou X,Chen H

更新日期：2008-03-01 00:00:00

abstract：:Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there i...

journal_title：Leukemia

authors： Shah N,Chari A,Scott E,Mezzi K,Usmani SZ

更新日期：2020-04-01 00:00:00

abstract：:MK-0457, an Aurora kinase and BCR-ABL inhibitor, was studied on a Phase I/II study in 77 patients with refractory hematologic malignancies. The average number of cycles per patient was 3 (range 1-21). Maximum tolerated doses for a 5-day short infusion and continuous infusion regimens were 40 mg/m(2)/h and 144 mg/m(2)/...

journal_title：Leukemia

authors： Giles FJ,Swords RT,Nagler A,Hochhaus A,Ottmann OG,Rizzieri DA,Talpaz M,Clark J,Watson P,Xiao A,Zhao B,Bergstrom D,Le Coutre PD,Freedman SJ,Cortes JE

更新日期：2013-01-01 00:00:00

abstract：:Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), d...

journal_title：Leukemia

authors： Lange T,Hubmann M,Burkhardt R,Franke GN,Cross M,Scholz M,Leiblein S,Al-Ali HK,Edelmann J,Thiery J,Niederwieser D

更新日期：2011-03-01 00:00:00

abstract：:Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this...

journal_title：Leukemia

authors： Othus M,Kantarjian H,Petersdorf S,Ravandi F,Godwin J,Cortes J,Pierce S,Erba H,Faderl S,Appelbaum FR,Estey E

更新日期：2014-02-01 00:00:00

abstract：:Bovine leukemia virus-infected sheep were demonstrated to possess a plasma factor that specifically suppresses in vitro virus expression in lymphocyte cultures. This blocking activity is observed even after phytohemagglutinin (PHA) stimulation and is independent of cellular proliferation. Such a factor may play a crit...

journal_title：Leukemia

authors： Cornil I,Levy D

更新日期：1989-02-01 00:00:00

abstract：:The phenotypic expression of genetically determined resistance to radiation leukemia virus (RadLV)-induced leukemia in mice has been shown to reside in the bone marrow. Because the bone marrow contains precursors of natural killer (NK) cells, known to play a role in retrovirally induced infections, and because these c...

journal_title：Leukemia

authors： St-Pierre Y,Hugo P,Lemieux S,Lussier G,Potworowski EF

更新日期：1988-08-01 00:00:00

abstract：:The tie receptor tyrosine kinase mRNA was originally identified as an amplified product in reverse transcription-polymerase chain reaction analysis of human K562 leukemia cell RNA. In situ hybridization analysis revealed that the corresponding mouse gene is expressed predominantly in endothelial cells. We have explore...

journal_title：Leukemia

authors： Armstrong E,Korhonen J,Silvennoinen O,Cleveland JL,Lieberman MA,Alitalo R

更新日期：1993-10-01 00:00:00

abstract：:The c-kit proto-oncogene encodes a receptor tyrosine kinase that is known to play a crucial role in mast cell growth and differentiation. In a human mast cell leukemia cell line (HMC-1), KitR was found to be constitutively phosphorylated on tyrosine, activated and associated with phosphatidylinositol 3-kinase (P13K) i...

journal_title：Leukemia

authors： Kanakura Y,Furitsu T,Tsujimura T,Butterfield JH,Ashman LK,Ikeda H,Kitayama H,Kanayama Y,Matsuzawa Y,Kitamura Y

更新日期：1994-04-01 00:00:00

abstract：:Upregulation of the immunosuppressive cell surface glycoprotein, CD200, is a common feature of acute myeloid leukemia (AML) and is associated with poor patient outcome. We investigated whether CD200 overexpression on AML cells could specifically compromise patient natural killer (NK) cell anti-tumor responses. We foun...

journal_title：Leukemia

authors： Coles SJ,Wang EC,Man S,Hills RK,Burnett AK,Tonks A,Darley RL

更新日期：2011-05-01 00:00:00

abstract：:max 41 transgenic mice consistently exhibit elevated numbers of mature granulocytes and monocytes in the peripheral blood and of immature and mature cells of these lineages in the marrow, spleen, lymph nodes and liver. The immature populations are not autonomous and exhibit a normal quantitative responsiveness to prol...

journal_title：Leukemia

authors： Metcalf D,Roberts AW,Willson TA

更新日期：1996-02-01 00:00:00

abstract：:Many genes are involved in cell cycle control, DNA repair and induction of cell death. Alterations in these genes have been responsible for the development of cancer as well as for resistance to cancer therapy. Recently, an emerging family of bcl2-like genes has been identified that plays a role in the regulation of c...

journal_title：Leukemia

authors： Meijerink JP,Smetsers TF,Slöetjes AW,Linders EH,Mensink EJ

更新日期：1995-11-01 00:00:00

abstract：:Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in childhood acute lymphoblastic leukemia (ALL). The 10-year update on the I-BFM-SG MRD study 91 demonstrates stable results (event-free survival), that is, standard ri...

journal_title：Leukemia

authors： Flohr T,Schrauder A,Cazzaniga G,Panzer-Grümayer R,van der Velden V,Fischer S,Stanulla M,Basso G,Niggli FK,Schäfer BW,Sutton R,Koehler R,Zimmermann M,Valsecchi MG,Gadner H,Masera G,Schrappe M,van Dongen JJ,Biondi A,B

更新日期：2008-04-01 00:00:00

abstract：:Prevailing wisdom holds that hematopoietic stem cells (HSCs) are predominantly quiescent. Although HSC cycle status has long been the subject of scrutiny, virtually all marrow stem cell research has been based on studies of highly purified HSCs. Here we explored the cell cycle status of marrow stem cells in un-separat...

journal_title：Leukemia

authors： Goldberg LR,Dooner MS,Johnson KW,Papa EF,Pereira MG,Del Tatto M,Adler DM,Aliotta JM,Quesenberry PJ

更新日期：2014-04-01 00:00:00

abstract：:Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration subsequent to SCT may prevent relapse, but the role of scheduling and its impact on outcome are not known. In a prospective, randomized multicente...

journal_title：Leukemia

authors： Pfeifer H,Wassmann B,Bethge W,Dengler J,Bornhäuser M,Stadler M,Beelen D,Vucinic V,Burmeister T,Stelljes M,Faul C,Dreger P,Kiani A,Schäfer-Eckart K,Schwerdtfeger R,Lange E,Kubuschok B,Horst HA,Gramatzki M,Brück P,S

更新日期：2013-06-01 00:00:00

abstract：:Imatinib has pronounced antileukemic activity in Ph+ALL, although responses are usually short. To determine whether imatinib may facilitate allogeneic SCT in relapsed or refractory Ph+ALL, we evaluated 46 consecutive, not previously transplanted patients who were enrolled in phase II studies of imatinib. Of 30 patient...

journal_title：Leukemia

authors： Wassmann B,Pfeifer H,Scheuring U,Klein SA,Gökbuget N,Binckebanck A,Martin H,Gschaidmeier H,Hoelzer D,Ottmann OG

更新日期：2002-12-01 00:00:00

abstract：:v-erb-B is the principal transforming gene of avian erythroblastosis virus, a replication defective retrovirus that transforms erythroid and fibroblast cells in vitro and causes erythroleukemia and fibrosarcoma in vivo. We have used a recombinant murine retrovirus, based on the truncated genome of Moloney murine leuke...

journal_title：Leukemia

authors： Miller M,Kennewell A,Symonds G

更新日期：1992-01-01 00:00:00